摘要
gp41是HIV-1表面的一种包膜糖蛋白,介导病毒粒子与宿主细胞的细胞膜发生膜融合从而使病毒进入靶细胞,在HIV-1感染和传播的过程中起关键作用。以gp41为靶点的融合抑制剂不失为一种新型的抗HIV-1药物之选,其中2003年多肽类融合抑制剂T-20的上市,使得多肽融合抑制剂成为备受关注的研究热点。本文就gp41的结构、融合机制以及肽类融合抑制剂的研究进展进行了综述。
The transmembrane glycoprotein gp41 of HIV-1 plays a key role in HIV-1 infection and transmission,mediating the fusion of virus and target cell membranes. Developing various peptides and peptidomimetics used as fusion inhibitors have became an attractive research area since the first peptide fusion inhibitor（ T-20） targeting HIV-1 gp41 approved by FDA in 2003.This review summarizes the structure and fusion mechanism of gp41 and the recent progresses in the design and development of novel peptides and peptidominetics used as HIV-1 fusion inhibitors.
出处
《临床医学》
CAS
2016年第3期117-120,F0003,F0004,共6页
Clinical Medicine
